In vivo and in vitro dabrafenib was used to treat NBL patients with BRAF V600 mutation (Kieran et al., 2019) and SHP2 inhibitors combined with vemurafenib could treat relapsed neuroblastoma (Valencia-Sama et al., 2020). The gene discussed is BRAF; the disease is neuroblastoma.